Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression
Christopher Groth, Xiaoying Hu, Rebekka Weber, et al.
British Journal of Cancer (2018) Vol. 120, Iss. 1, pp. 16-25
Open Access | Times Cited: 664

Showing 1-25 of 664 citing articles:

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 750
Lipid metabolism in cancer: New perspectives and emerging mechanisms
Lindsay A. Broadfield, Antonino Alejandro Pane, Ali Talebi, et al.
Developmental Cell (2021) Vol. 56, Iss. 10, pp. 1363-1393
Open Access | Times Cited: 406
Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer
Andrew M. K. Law, Fátima Valdés‐Mora, David Gallego‐Ortega
Cells (2020) Vol. 9, Iss. 3, pp. 561-561
Open Access | Times Cited: 379
Therapeutic targeting of the hypoxic tumour microenvironment
Dean C. Singleton, Andrew Macann, William R. Wilson
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 12, pp. 751-772
Closed Access | Times Cited: 329
Lactic Acid and an Acidic Tumor Microenvironment suppress Anticancer Immunity
Joy X. Wang, Stephen Yiu Chuen Choi, Xiaojia Niu, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8363-8363
Open Access | Times Cited: 282
Oral squamous cell carcinomas: state of the field and emerging directions
Yunhan Tan, Zhihan Wang, Mengtong Xu, et al.
International Journal of Oral Science (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 259
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion
Paola De Cicco, Giuseppe Ercolano, Angela Ianaro
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 258
CCL2/CCR2 signaling in cancer pathogenesis
Qiongyu Hao, Jaydutt V. Vadgama, Piwen Wang
Cell Communication and Signaling (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 239
Understanding the tumor microenvironment for effective immunotherapy
Habib Sadeghi Rad, James Monkman, Majid Ebrahimi Warkiani, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 3, pp. 1474-1498
Open Access | Times Cited: 233
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Rebekka Weber, Christopher Groth, Samantha Lasser, et al.
Cellular Immunology (2020) Vol. 359, pp. 104254-104254
Closed Access | Times Cited: 233
Programmed Cell Death Tunes Tumor Immunity
Jing Liu, Minjing Hong, Yijia Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 212
Combating Implant Infections: Shifting Focus from Bacteria to Host
Saber Amin Yavari, Suzanne M. Castenmiller, Jos A. G. van Strijp, et al.
Advanced Materials (2020) Vol. 32, Iss. 43
Open Access | Times Cited: 186
Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
Antonino Bruno, Lorenzo Mortara, Denisa Baci, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 182
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development
María Ochoa de Olza, Blanca Navarro Rodrigo, Stefan Zimmermann, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 9, pp. e419-e430
Closed Access | Times Cited: 178
Complementing the Cancer-Immunity Cycle
Rubén Pı́o, Daniel Ajona, Sergio Ortiz‐Espinosa, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 174
Humanized mouse models for immuno-oncology research
Jane Chuprin, Hannah Buettner, Mina O. Seedhom, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 3, pp. 192-206
Open Access | Times Cited: 166
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney, Karl D. Lewis, Harriet M. Kluger, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005755-e005755
Open Access | Times Cited: 151
DNMT1: A key drug target in triple-negative breast cancer
Kah Keng Wong
Seminars in Cancer Biology (2020) Vol. 72, pp. 198-213
Closed Access | Times Cited: 144
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Zhengyi Wang, Xiaoying Wu
Cancer Medicine (2020) Vol. 9, Iss. 21, pp. 8086-8121
Open Access | Times Cited: 143
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment
Maximilian Haist, Henner Stege, Stephan Grabbe, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 210-210
Open Access | Times Cited: 137
Myeloid-derived suppressor cells in cancer and cancer therapy
Samantha Lasser, Feyza Gül Özbay Kurt, Ihor Arkhypov, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 147-164
Closed Access | Times Cited: 132
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy
Qiang Lü, Dongquan Kou, Shenghan Lou, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 131
Cancer immunotherapy: it’s time to better predict patients’ response
Charlotte Pilard, Marie Ancion, Philippe Delvenne, et al.
British Journal of Cancer (2021) Vol. 125, Iss. 7, pp. 927-938
Open Access | Times Cited: 126
Cytokine‐ and chemokine‐induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy
Ajaz A. Bhat, Sabah Nisar, Mayank Singh, et al.
Cancer Communications (2022) Vol. 42, Iss. 8, pp. 689-715
Open Access | Times Cited: 118
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
Xueke Shi, Jin Yang, Shuzhi Deng, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 108
Page 1 - Next Page

Scroll to top